Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Working Adults Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Cost Effective Health Promotion for Older Adults

NCT00953030
View directory record Official record
Conditions
Working Adults
Interventions
COACH, RealAge
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2009 · Synced Jul 21, 2026, 5:31 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
904 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

NCT00020657
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dolasetron mesylate, granisetron hydrochloride, ondansetron, prochlorperazine, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jul 21, 2026, 5:31 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

NCT05133531
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
Ravulizumab, Pozelimab, Cemdisiran, Eculizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Active, not recruiting Phase 2 Interventional Results available

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

NCT03264131
View directory record Official record
Conditions
Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases
Interventions
Brentuximab Vedotin, CHEP
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
4
States / cities
Hollywood, Florida • Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

NCT06602726
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
REGN1908, REGN1909, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Pozelimab + Cemdisiran, Cemdisiran, Placebo, Pozelimab
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

NCT05915702
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Indian Wells, California • Orange, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Three-Part Program for Parents With Premature Infants

NCT00056680
View directory record Official record
Conditions
Premature Birth
Interventions
Psychoeducational video, Infant massage, Brazelton Neonatal Behavioral Assessment Scale
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
32 Weeks to 37 Weeks
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2007 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

NCT05564117
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Costa Mesa, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

TMS for Investigating Memory Facilitation

NCT05462782
View directory record Official record
Conditions
Age-associated Memory Impairment
Interventions
Transcranial Magnetic Stimulation (TMS) Cone Coil, Transcranial Magnetic Stimulation (TMS) Sham Coil
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
60 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Jul 21, 2026, 5:31 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

NCT05800015
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
29
States / cities
Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT05656911
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Zabedosertib (BAY1834845), Placebo to zabedosertib (BAY1834845)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Skokie, Illinois • Boston, Massachusetts • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transcranial Electrical Stimulation on Task Performance in Healthy Adults

NCT06995560
View directory record Official record
Conditions
Healthy, Brain Stimulation, Transcranial Direct Current Stimulation (tDCS), Cognition, Psychomotor Performance, Neurophysiology
Interventions
Active Transcranial Electrical Stimulation, Sham Transcranial Electrical Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Not yet recruiting Not applicable Interventional

Evaluation of the Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study

NCT07634146
View directory record Official record
Conditions
Migraine, Migraine Disease, Migraine Disorder, Migraine Headache, Migraine Disability, Migraine in Adults, Menstrual Migraine, Menstrual Migraine (MM) Headaches
Interventions
Foundational dietary supplement, Luteal phase dietary supplement add-on, Migraine phase dietary supplement add-on, Reference dietary supplement
Dietary Supplement
Lead sponsor
Miracle Wellness LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lutherville-Timonium, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

NCT01080807
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Matching Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Video Chat Intervention for Enhancing Self-efficacy for Lifestyle Physical Activity

NCT03906955
View directory record Official record
Conditions
Physical Activity, Self Efficacy, Working Adults
Interventions
Efficacy for Lifestyle PA, Efficacy for Work-life Balance
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
25 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Multidisciplinary Team Approach: Working Together to Improve Glycemic Control in Hispanic Adults Diabetes

NCT03463629
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Specialized multidisciplinary diabetes team (SMDT) approach, Traditional model of care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit

NCT00996320
View directory record Official record
Conditions
Sleep Deprivation, Depression
Interventions
Reduced work hour schedule
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Jul 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Online Evaluation of Work Chat

NCT05949086
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Work Chat
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 21, 2026, 5:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Infant Immune Response to Bacterial Infection

NCT00546195
View directory record Official record
Conditions
Prematurity, Histologic Chorioamnionitis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 5:31 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 5:31 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects

NCT00449709
View directory record Official record
Conditions
Obstetric Labour, Premature, Premature Ejaculation
Interventions
GSK221149
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Jul 21, 2026, 5:31 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951
View directory record Official record
Conditions
Melanoma
Interventions
cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 21, 2026, 5:31 PM EDT